TransMedics Group Inc. (TMDX)
Is TransMedics Stock a Buy Before 2025?
In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Down Over 60%, Is TransMedics Stock a Buy on the Dip?
TransMedics Group (TMDX 3.03%) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August.
Why Transmedics Group Stock Plummeted 21% This Week
Shares of Transmedics Group (TMDX 2.13%) sank over 20% this week, according to data from S&P Global Market Intelligence. The organ transplant disrupter announced a CFO transition and reduced the range for its full-year 2024 guidance, indicating slowing revenue growth.
TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024
TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance. The company faces near-term challenges, but long-term growth prospects remain strong. The CEO suggested a temporary pause in growth at the Piper Sandler conference this week, with stronger performance expected in 2H 2025, driven by clinical data from heart and lung programs.
Why TransMedics Stock Plummeted Today
Shares of leading organ transplant platform TransMedics (TMDX -15.43%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.
Is TMDX Stock a Buy, Sell or Hold at a P/S Multiple of 5.02X?
TransMedics is facing a softness in demand for transplant services in the United States. Moreover, rising costs raise concern.
1 Top Growth Stock Down 56% to Buy After Its Recent Pullback
In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
TransMedics: Long-Term Thesis Hasn't Changed At All
TMDX's Q3 revenue miss and margin contraction are short-term issues; long-term growth potential remains strong with management's guidance of 4,000 transplants this year and 10,000 in 3-5 years. High expectations led to a stock price drop, but management's clear communication on seasonal trends and market share stability supports the long-term thesis. TMDX is undervalued compared to peers like Intuitive Surgical and PROCEPT BioRobotics, with significant revenue growth potential and a unique market position.
Is TransMedics Group Stock a Buy?
This organ transplant specialist is down, but still has plenty of signs of life.
TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
TransMedics' Q3 results were weak, with revenue declining sequentially due to US transplant volume headwinds and scheduled aircraft maintenance. While the growth of TransMedics' current business is likely to continue moderating, there remain large opportunities internationally and in other organs. This is highlighted by the fact that TransMedics reiterated its longer-term transplant volume target, despite current weakness.
Shareholders that Lost Money on TransMedics Group, Inc. (TMDX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TMDX
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
TMDX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by TransMedics Group, Inc.
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
